Detalhe da pesquisa
1.
[A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Gan To Kagaku Ryoho
; 46(10): 1595-1597, 2019 Oct.
Artigo
em Japonês
| MEDLINE | ID: mdl-31631147
2.
Pharmacokinetics and Safety of Vilazodone in Hepatic Impairment.
Am J Ther
; 22(4): 269-77, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25474324
3.
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res
; 27(1): 34-42, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082208
4.
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.
Thyroid
; 30(9): 1384-1389, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292131
5.
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
J Thorac Oncol
; 15(4): 541-549, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31988000
6.
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923911
7.
Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Blood Adv
; 3(22): 3499-3502, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725893
8.
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.
JCO Precis Oncol
; 32019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31485557